These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1828188)

  • 1. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
    Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
    Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
    Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
    Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
    Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
    Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
    Lin JT; Cashmore AR; Baker M; Dreyer RN; Ernstoff M; Marsh JC; Bertino JR; Whitfield LR; Delap R; Grillo-Lopez A
    Cancer Res; 1987 Jan; 47(2):609-16. PubMed ID: 2947679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
    Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
    Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
    Schilsky RL; O'Laughlin K; Ratain MJ
    Cancer Res; 1986 Aug; 46(8):4184-8. PubMed ID: 3731086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
    Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase I study of CI-898. CI-898 Study Group].
    Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
    Allegra CJ; Jenkins J; Weiss RB; Balis F; Drake JC; Brooks J; Thomas R; Curt GA
    Invest New Drugs; 1990 May; 8(2):159-66. PubMed ID: 2143500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.